Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin versus heparin + vancomycin + amikacin lock for prevention of tunneled hemodialysis catheter infection
IRCT20210317050735N1Phase 2Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Feb 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of heparin, vancomycin and amikacin in catheter infection (2 arms), sponsored by Ardabil University of Medical Sciences. Primary endpoint: Infection. Started Feb 2023; status: completed.
02
Drugs
heparinvancomycinamikacin
03
Conditions
catheter infection
Beyond the preview
Go deeper on IRCT20210317050735N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210317050735N1.